

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P29865Application No.
10/577,487INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Koichi SHUDO et al.Filing Date
I.A. Filed October 28, 2004Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/M.F./	2004 / 0 2 5 9 8 7 7	12/23/04	MUTO et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/M.F./	0 2 / 4 9 6 3 2	06/27/02	W.I.P.O.	ABSTRACT ONLY		CONSIDERED
/M.F./	1 3 5 2 6 5 0	10/15/03	E.P.O.			
/M.F./	02 / 0 6 4 0 6 5	08/22/02	W.I.P.O.			
	2 0 0 2 5 2 8 4 2 0	09/03/02	JAPAN			
/M.F./	0 0 / 2 4 4 1 2	05/04/00	W.I.P.O.			
	2 0 0 3 5 1 1 1 1 0	03/25/03	JAPAN			
/M.F./	0 1 / 2 4 8 6 6	04/12/01	W.I.P.O.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/M.F./	1	Yamasaki, K., et al., "Inhibition of NFkB Activation Using cis-Element 'Decoy' of NFkB Binding Site Reduces Site Neointimal Formation in Porcine Balloon-Injured Coronary Artery Model," <u>Gene Therapy</u> , Vol. 10: 356-364 (2003).
/M.F./	2	Yoshimura, S., et al., "Inhibition of Intimal Hyperplasia after Balloon Injury in Rat Carotid Artery Model Using cis-Element 'Decoy' of Nuclear factor-κB Binding Site as a Novel Molecular Strategy," <u>Gene Therapy</u> , Vol. 8: 1635-1642 (2001).
/M.F./	3	Kozuma, K., "Drug Eluting Stent," <u>Coronary Intervention</u> , Vol. 1, No. 1: 58-62 (2002), accompanied by an English language translation thereof.
/M.F./	4	Hiatt, B., et al., "Drug Eluting Stents for the Prevention of Restenosis: In Quest for the Holy Grail," <u>Catheterization and Cardiovascular Interventions</u> , Vol. 55: 409-417 (2002).
/M.F./	5	Curfman, G. D., "Sirolimus-Eluting Coronary Stents," <u>New England Journal of Medicine</u> , Vol. 346, No. 23: 1770-1771 (June 6, 2002).
/M.F./	6	Morice, M., et al., "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization," <u>New England Journal of Medicine</u> , Vol. 346, No. 23: 1773-1780 (June 6, 2002).

EXAMINER /Meghan Finn/

DATE CONSIDERED 07/26/2009

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.